The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1768
Two New Blood Tests for Alzheimer's Disease
PDF:   US English
Disclosures
Principal Faculty
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Discuss the role of testing blood for biomarkers of brain amyloid pathology in patients with symptoms of cognitive decline.
 Select a term to see related articles  Alzheimer's disease   donanemab   Elecsys Phospho-Tau   Kisunla   lecanemab   Leqembi   Lumipulse G   PrecivityAD2 
Med Lett Drugs Ther. 2026 Nov 23;68(1768):185-6   doi:10.58347/tml.2026.1768a
Key Points: Blood Biomarker Testing for Alzheimer's Disease
  • Newly FDA-cleared blood tests that detect biomarkers correlated with brain amyloid pathology have high positive and negative predictive value for existing brain amyloid pathology in patients with symptoms of cognitive decline.
  • Patients with a positive result should be referred for an amyloid PET scan or CSF biomarker testing.
  • Blood biomarker tests should be not be used for screening purposes in asymptomatic patients.

Two new blood tests for biomarkers that correlate with brain amyloid beta pathology have been cleared by the FDA to aid in the diagnosis of Alzheimer's disease (AD): Elecsys Phospho-Tau (217P) Plasma assay (Roche) and PrecivityAD2 (C2N Diagnostics). Other FDA-cleared blood tests for AD biomarkers are listed in Table 1.1,2 The amyloid beta-directed antibodies lecanemab (Leqembi, and others) and donanemab (Kisunla) are available for treatment of AD in patients with mild cognitive impairment or mild dementia who have confirmed brain amyloid pathology.3

BIOMARKERS IN AD ― Detection of AD biomarkers in blood (e.g., beta-amyloid [Aβ], phosphorylated Tau [pTau]) has been shown to correlate with the presence of amyloid beta pathology in the brain. Standard tests for detection of brain amyloid beta pathology include amyloid PET scans and cerebrospinal fluid (CSF) biomarker tests.4,5

Blood tests for AD biomarkers are intended to aid in the initial assessment of patients who are exhibiting signs of cognitive decline. They can be used in primary care settings or by a specialist. A positive result does not establish a diagnosis of AD; patients with a positive test should be referred for an amyloid PET scan or CSF biomarker testing. Blood biomarker tests should not be used as a screening tool for AD in asymptomatic patients.

ELECSYS PHOSPHO-TAU (217P) ― The Elecsys Phospho-Tau (217P) Plasma assay, which is FDA-cleared for use in patients ≥55 years old with signs, symptoms, or complaints of cognitive decline, measures levels of Tau protein phosphorylated at threonine 217 (pTau217) in human plasma. pTau217 appears to be more reliable for detection of amyloid beta pathology than pTau181, which is the biomarker measured in the previously-cleared Elecsys Phospho-Tau (181P) Plasma test.6-8 The likelihood of brain amyloid beta pathology is high with a positive result and low with a negative result.

Clinical Studies – FDA clearance of the Elecsys Phospho-Tau (217P) Plasma assay was based on the results of a clinical trial (summarized in the FDA review document) that compared it with amyloid PET imaging in 958 patients 55-85 years old with cognitive complaints or impairment. Among 445 patients with a negative result on the Elecsys pTau217 blood test, 424 also had a negative amyloid PET scan (negative predictive value 95.3%). Of the 322 patients with a positive result on the Elecsys pTau217 blood test, 285 also had a positive amyloid PET scan (positive predictive value 88.5%). Of the 580 patients with a negative amyloid PET scan, 37 had a positive Elecsys pTau217 blood test, corresponding to a false-positive rate of 3.6%.9,10

PRECIVITYAD2 ― PrecivityAD2, which is FDA-cleared for use in adults ≥40 years old who have signs or symptoms of mild cognitive impairment, measures plasma levels of pTau217 and beta-amyloid proteins (Aβ40 and 42; Aβ42 is more likely to form plaques in the brain than Aβ40). The ratios of pTau217 to nonphosphorylated Tau217 (pTau217/npTau217) and beta-amyloid 42 to beta-amyloid 40 (Aβ42/40) are used to calculate an Amyloid Probability Score 2 (APS2; range 0-100) to determine a positive or negative result. A negative result (APS2 score of 0-47) indicates a low likelihood of brain amyloid beta pathology and a positive result (APS2 score of 48-100) indicates a high likelihood of amyloid plaques in the brain.11

Clinical Studies – FDA clearance of PrecivityAD2 was based on the results of a clinical trial (summarized in the FDA review document) that compared it to an amyloid PET scan or a CSF biomarker test in 1142 patients ≥40 years old with signs or symptoms of cognitive decline. Among patients with a positive result on the PrecivityAD2 test, 97.6% had amyloid beta pathology detected by reference methods (positive predictive value 97.6%). A "likely positive" result occurred in 17.3% of patients and had a positive predictive value of 77.3%. Among patients with a negative PrecivityAD2 test result, 93.1% did not have amyloid beta pathology detected by reference methods (negative predictive value 93.1%).

Table 1. FDA-Cleared Plasma Biomarker Tests for Alzheimer's Disease
Test
Elecsys Phospo-Tau (181P)
Elecsys Phospo-Tau (217P)
Lumipulse G
PrecivityAD21
Manufacturer
Roche
Roche
Fujirebio
C2N Diagnostics
Biomarkers
Measured
pTau181
pTau217
pTau217/Aβ42 ratio
Aβ42/40 + pTau217/
npTau217 ratio combined
into the Amyloid Probability
Score 2 (APS2)
Indication
Aid in initial assessment
of AD and other causes of
cognitive decline
Aid in detection of amyloid
pathology associated with
AD
Early detection of amyloid
pathology associated with
AD
Aid in evaluation of AD or
other causes of cognitive
decline
Population
≥55 years old with signs,
symptoms, or complaints
of cognitive decline
≥55 years old with signs,
symptoms, or complaints
of cognitive decline
≥50 years old with signs
or symptoms of AD
≥40 years old with signs
or symptoms of MCI or
dementia
Comments
Recommended for use in
primary care settings
Can only rule out amyloid
pathology
NPV: 97.9%; PPV: 22.4%
Can be used in primary
care settings or by a
specialist
Can be used to identify
or rule out amyloid
pathology
NPV 95.3%; PPV 88.5%
Recommended for use by
specialists
Can be used to identify
or rule out amyloid
pathology
NPV: 97.3%; PPV: 91.7%
Can be used in primary care
settings or by a specialist
Can be used to identify or
rule out amyloid pathology
NPV 93.1%; PPV 97.6%
Result
Interpretation
Negative: amyloid
pathology unlikely
Positive: further
evaluation needed
Negative: amyloid
pathology unlikely
Positive: further
evaluation needed
Negative: amyloid
pathology unlikely
Positive: further
evaluation needed
Negative: amyloid pathology
unlikely
Positive: further evaluation
needed
Aβ = beta-amyloid; pTau = phosphorylated Tau; np = nonphosphorylated Tau; NPV = negative predictive value; PPV = positive predictive value;
MCI = mild cognitive impairment
1. Replaces the PrecivityAD test, which is used to quantify the Aβ42/40 ratio.

CONCLUSION ― The Elecsys Phospho-Tau (217P) and PrecivityAD2 blood tests are effective in identifying or ruling out brain amyloid beta pathology in patients with signs of cognitive decline undergoing evaluation for Alzheimer's disease. Patients with a positive result on either test should be referred for further testing. pTau217 appears to be more reliable for detection of amyloid beta pathology than pTau181, the biomarker measured in the Elecsys Phospho-Tau (181P) Plasma test. Blood biomarker tests for AD should not be used for screening purposes in asymptomatic patients.

REFERENCES

  1. A blood test for Alzheimer's disease. Med Lett Drugs Ther 2025; 67:109.
  2. Elecsys – a second blood test for Alzheimer's disease. Med Lett Drugs Ther 2026; 68:18.
  3. Drugs for dementia. Med Lett Drugs Ther 2026; 68:49.
  4. CR Jack Jr et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer's Association Workgroup. Alzheimers Dement 2024; 20:5143. doi:10.1002/alz.13859
  5. M Schöll et al. Challenges in the practical implementation of blood biomarkers for Alzheimer's disease. Lancet Healthy Longev 2024; 5:100630. doi:10.1016/j.lanhl.2024.07.013
  6. J Therriault et al. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2025; 24:740. doi:10.1016/s1474-4422(25)00227-3
  7. SE Schindler et al. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology. Alzheimers Dement 2024; 20:8074. doi:10.1002/alz.14315
  8. N Warmenhoven et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 2025; 148:416. doi:10.1093/brain/awae346
  9. DP Hibar et al. Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts. Alzheimers Dement 2026; 22:e71009. doi:10.1002/alz.71009
  10. FDA. 510(k) substantial equivalence determination decision summary. K261686. Elecsys Phospho-Tau (217P) plasma. Available at: https://bit.ly/4i8606K. Accessed October 30, 2026.
  11. S Palmqvist et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 2024; 332:1245. doi:10.1001/jama.2024.13855
Important Copyright and Disclaimer Message: The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited. Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited. By accessing and reading the attached content I agree to comply with US and international copyright law and these terms and conditions of The Medical Letter, Inc.

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
arrow to previous article
arrow to next article